Jürg Eckhardt

The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs.

One Drop is the worlds leading diabetes management platform. With an award-winning mobile app, the best bluetooth-enabled blood glucose meter, test strip and lancet subscriptions, and personalized diabetes coaching, One Drop makes diabetes management simple and successful.

Ada is a global health company created by doctors to improve human health by transforming knowledge into better outcomes. Ada is the worlds most popular symptom assessment app, with 13 million users and 32 million completed assessments. Every three seconds, someone turns to Ada for personal health guidance. Our powerful enterprise solutions help partners inform health decisions, triage to appropriate care, and reduce avoidable costs. We work with healthcare systems and providers, insurers, payers and commissioners, life sciences, employers, governments, and non-profits.

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing a suite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome.

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.

Rewriting the next 100 years of farming

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma’s technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.

ALEVA is 👉THE COMPANY THAT INTRODUCED Directional Deep Brain Stimulation in Neuromodulation treatments and our clinically proven technology has set the industry standard for directional leads* Today we are 👉A SOLID COMPANY that following directSTIM™'s CE marking have started our commercial journey by partnering with the most important neurological clinics in Germany, with the goal to soon reach the most relevant European markets. We understand that if we want to help OUR CUSTOMERS, overcome their challenges, we need to 👉COMBINE SPECIALISATION with the 👉COMMITMENT TO BE RESPONSIVE to the everyday new challenges they experience. This is the attitude you will find in every ALEVA employee and sales representative who will be in contact with you. We are the 👉ONLY EUROPEAN COMPANY that designs, manufactures, and commercialises DBS devices for the treatment of Parkinson’s disease and essential tremor. Our production and R&D headquarters based in Switzerland complies to the highest quality standard for the highest safety of patients worldwide. Our A VISIONARY PROJECT SUSTAINED BY SOLID FOUNDATIONS: 👉a new group of investors that will sustain the completion of OUR PROJECT 👉a reinforced executive team who is complementing the existing successful group to partner with Neurosurgeons and Neurologists in the effective deployment of our Vision. *May 28, 2014 http://doi.org/10.1093/brain/awu102.

Cameron Health is a medical device developer based in San Clemente, California, USA. Cameron Health has its European office, Cameron Health BV, in Arnhem, The Netherlands. The privately-held company's focus is on the development and manufacture of a new generation of implantable cardioverter-defibrillator (ICD) implanted completely subcutaneously, called a Subcutaneous Implantable Defibrillator (S-ICD®). Cameron Health's approach avoids implanting leads in or on the heart, which has been the usual procedure for cardiac devices. Instead, the Cameron ICD is entirely implanted outside the thoracic wall.

The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs.

One Drop is the worlds leading diabetes management platform. With an award-winning mobile app, the best bluetooth-enabled blood glucose meter, test strip and lancet subscriptions, and personalized diabetes coaching, One Drop makes diabetes management simple and successful.

Ada is a global health company created by doctors to improve human health by transforming knowledge into better outcomes. Ada is the worlds most popular symptom assessment app, with 13 million users and 32 million completed assessments. Every three seconds, someone turns to Ada for personal health guidance. Our powerful enterprise solutions help partners inform health decisions, triage to appropriate care, and reduce avoidable costs. We work with healthcare systems and providers, insurers, payers and commissioners, life sciences, employers, governments, and non-profits.

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing a suite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome.

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/